Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

46 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Multidisciplinary recommendations for essential baseline functional and laboratory tests to facilitate early diagnosis and management of immune-related adverse events among cancer patients.
Özdemir BC, Espinosa da Silva C, Arangalage D, Monney P, Guler SA, Huynh-Do U, Stirnimann G, Possamai L, Trepp R, Hoepner R, Salmen A, Gerard CL, Hruz P, Christ L, Rothschild SI. Özdemir BC, et al. Cancer Immunol Immunother. 2023 Jul;72(7):1991-2001. doi: 10.1007/s00262-023-03436-0. Epub 2023 Apr 5. Cancer Immunol Immunother. 2023. PMID: 37017694 Free PMC article. Review.
[Cardiotoxicity of immune checkpoint inhibitors used in cancer treatment].
Arangalage D, Pavon AG, Hugelshofer S, Desgraz B, Tzimas G, Delyon J, Muller O, Obeid M, Ribi C, Michielin O, Özdemir BC, Monney P. Arangalage D, et al. Among authors: ozdemir bc. Rev Med Suisse. 2020 Jun 3;16(696):1165-1168. Rev Med Suisse. 2020. PMID: 32496706 Review. French.
Late-onset and long-lasting immune-related adverse events from immune checkpoint-inhibitors: An overlooked aspect in immunotherapy.
Ghisoni E, Wicky A, Bouchaab H, Imbimbo M, Delyon J, Gautron Moura B, Gérard CL, Latifyan S, Özdemir BC, Caikovski M, Pradervand S, Tavazzi E, Gatta R, Marandino L, Valabrega G, Aglietta M, Obeid M, Homicsko K, Mederos Alfonso NN, Zimmermann S, Coukos G, Peters S, Cuendet MA, Di Maio M, Michielin O. Ghisoni E, et al. Among authors: ozdemir bc. Eur J Cancer. 2021 May;149:153-164. doi: 10.1016/j.ejca.2021.03.010. Epub 2021 Apr 14. Eur J Cancer. 2021. PMID: 33865201 Free article.
Correction to: Multidisciplinary recommendations for essential baseline functional and laboratory tests to facilitate early diagnosis and management of immune‑related adverse events among cancer patients.
Özdemir BC, Espinosa da Silva C, Arangalage D, Monney P, Guler SA, Huynh-Do U, Stirnimann G, Possamai L, Trepp R, Hoepner R, Salmen A, Gerard CL, Hruz P, Christ L, Rothschild SI. Özdemir BC, et al. Cancer Immunol Immunother. 2023 Jul;72(7):2003-2004. doi: 10.1007/s00262-023-03456-w. Cancer Immunol Immunother. 2023. PMID: 37154850 Free PMC article. No abstract available.
Perioperative Chemoimmunotherapy With Durvalumab for Muscle-Invasive Urothelial Carcinoma: Primary Analysis of the Single-Arm Phase II Trial SAKK 06/17.
Cathomas R, Rothschild SI, Hayoz S, Bubendorf L, Özdemir BC, Kiss B, Erdmann A, Aeppli S, Mach N, Strebel RT, Hadaschik B, Berthold D, John H, Zihler D, Schmid M, Alborelli I, Schneider M, Musilova J, Spahn M, Petrausch U. Cathomas R, et al. Among authors: ozdemir bc. J Clin Oncol. 2023 Nov 20;41(33):5131-5139. doi: 10.1200/JCO.23.00363. Epub 2023 Aug 17. J Clin Oncol. 2023. PMID: 37590894 Free PMC article. Clinical Trial.
The role of immune checkpoint inhibitors in clinical practice: an analysis of the treatment patterns, survival and toxicity rates by sex.
Wahli MN, Hayoz S, Hoch D, Ryser CO, Hoffmann M, Scherz A, Schwacha-Eipper B, Häfliger S, Wampfler J, Berger MD, Novak U, Özdemir BC. Wahli MN, et al. Among authors: ozdemir bc. J Cancer Res Clin Oncol. 2023 Jul;149(7):3847-3858. doi: 10.1007/s00432-022-04309-2. Epub 2022 Aug 23. J Cancer Res Clin Oncol. 2023. PMID: 35997822 Free PMC article.
46 results